Vertaile menetelmiä

	Treatment Satisfaction Questionnaire for Medication (TSQM)	Lääkitysohjeiden Noudattamisen Arviointiasteikko (MARS)
Tieteenala	Farmakologia	Farmakologia
Menetelmäperhe	Process / pipeline	Process / pipeline
Syntyvuosi	2004	2000
Kehittäjä	Mary Jo Atkinson and colleagues	Kathryn Thompson, Jayashri Kulkarni, and Anthony A. Sergejew
Tyyppi	Self-report	Self-report
Alkuperäislähde	Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Berman, B. M., & Wolpert, B. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel of chronically ill individuals. Health and Quality of Life Outcomes, 2(1), 12.	Thompson, K., Kulkarni, J., & Sergejew, A. A. (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research, 42(3), 241-247.
Rinnakkaisnimet	TSQM	MARS
Liittyvät	4	4
Tiivistelmä	The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-item generic measure developed by Atkinson and colleagues in 2004 to assess patient satisfaction with medication across diverse therapeutic areas and disease conditions. It measures four key dimensions—Effectiveness, Side Effects, Convenience, and Global Satisfaction—with standardized 0–100 scoring, making it suitable for cross-disease comparison and health economic evaluation. The TSQM has become a standard outcome in pharmaceutical research, clinical trials, and real-world medication effectiveness studies.	The Medication Adherence Rating Scale (MARS) is a 10-item self-report measure developed by Thompson, Kulkarni, and Sergejew in 2000 to assess medication adherence behaviors and attitudes in psychiatric populations, particularly antipsychotic medication use. Although originally validated in schizophrenia, it has been successfully applied across diverse medical conditions including hypertension, diabetes, and chronic disease management, providing a quick, sensitive assessment of actual adherence frequency and admission of problematic medication-taking behaviors.